CROMSOURCE Adds Early Phase Research Unit to its Portfolio
CROMSOURCE srl, an international full service contract research organization announced the completion of a private-public deal with Centro Ricerche Cliniche di Verona (CRC), a modern early phase clinical research unit, founded in 2005. The CRC is located in Verona and is now under state and CROMSOURCE ownership.
The early phase clinical research facilities of the CRC occupy about 800 square metres of the 8th floor of the G.B. Rossi Hospital in Verona. The CRC provides full overnight accommodation and is equipped to state-of-the-art levels. Staff at the CRC has extensive international Pharma experience and the CRC is fully integrated within the local medical and scientific community. This provides access to highly motivated, well-defined patient populations and disease groups for Proof-of-Concept studies.
'We are delighted to welcome CRC and its expert team', stated Dr Oriana Zerbini, Chief Executive Officer of CROMSOURCE. 'For some time we have wanted to add early phase clinical trial capabilities to our comprehensive portfolio of services, and we have now found the perfect way to do so. With this collaboration CROMSOURCE truly becomes a full service CRO, able to provide our customers our support from the earliest part of their clinical development programs.'
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
